180 related articles for article (PubMed ID: 30205379)
1. The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
El-Haggar SM; Eissa MA; Mostafa TM; El-Attar KS; Abdallah MS
Psychother Psychosom; 2018; 87(6):331-339. PubMed ID: 30205379
[TBL] [Abstract][Full Text] [Related]
2. The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
Abdallah MS; Mosalam EM; Zidan AA; Elattar KS; Zaki SA; Ramadan AN; Ebeid AM
Neurotherapeutics; 2020 Oct; 17(4):1897-1906. PubMed ID: 32500486
[TBL] [Abstract][Full Text] [Related]
3. Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Merza Mohammad TA; Merza Mohammad TA; Salman DM; Jaafar HM
Pharmacopsychiatry; 2024 May; ():. PubMed ID: 38710206
[TBL] [Abstract][Full Text] [Related]
4. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
7. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
Farajollahi-Moghadam M; Sanjari-Moghaddam H; Ghazizadeh Hasemi M; Sanatian Z; Talaei A; Akhondzadeh S
Int Clin Psychopharmacol; 2021 May; 36(3):140-146. PubMed ID: 33724254
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
10. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
11. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
Abdallah MS; Ramadan AN; Omara-Reda H; Mansour NO; Elsokary MA; Elsawah HK; Zaki SA; Abo Mansour HE; Mosalam EM
CNS Neurosci Ther; 2021 Dec; 27(12):1540-1548. PubMed ID: 34545997
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
14. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
[TBL] [Abstract][Full Text] [Related]
20. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
Mowla A; Kardeh E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
